Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...
Background Historically, immunohistochemistry (IHC) assays have been designed for simplicity of manual pathology, however, this is not always ideal to acquire the appropriate data for patient selection and outcomes. Due to various challenges within the current...
In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article was published in the Journal: Clinical Cancer Research online first on June 3,...